All In Biotech

Drug Trial Radar · NCT04823130

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

A Multi-center, Exploratory Study to Assess Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

54

Actual

Start

Apr 22, 2021

Primary completion

Jun 30, 2022

Study completion Aug 30, 2022

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Mar 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objective: \- Assess change in neuronal architecture following long term treatment with dupilumab in skin biopsies from atopic dermatitis (AD) participants with chronic pruritus. Secondary Objectives: * Assess change in neuronal architecture following short term treatment with dupilumab and during follow-up in skin biopsies from AD participants with chronic pruritus. * To evaluate the efficacy of dupilumab in AD participants with chronic pruritus. * To evaluate the safety of dupilumab in adult participants with moderate-to-severe AD.

Conditions

  • Dermatitis Atopic

Interventions

  • Dupilumab (SAR231893)Drug

    Pharmaceutical form: solution for injection Route of administration: subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Intraepidermal Nerve Fiber Density on Lesional Skin at Week 17Time frame: Baseline, Week 17
  2. Percentage of Participants With Change From Baseline in Nerve Fiber Branching on Lesional Skin at Week 17Time frame: Baseline, Week 17

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 8400001

    Miami, Florida

  • Investigational Site Number 8400002

    East Windsor, New Jersey

  • Investigational Site Number 2760001

    Münster, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.